FRT
63
10
WMT
70
2
CHRW
44
2
RRC
46
-2
WY
60
7
ALLE
66
2
MPC
50
4
PGR
69
4
AAL
50
-3
SPG
53
2
DIS
54
2
NTRS
44
5
CMG
53
-11
DVA
80
4
ADM
33
5
PSX
34
2
SIG
57
7
PPL
67
5
RSG
65
3
VFC
56
11
FRT
63
10
WMT
70
2
CHRW
44
2
RRC
46
-2
WY
60
7
ALLE
66
2
MPC
50
4
PGR
69
4
AAL
50
-3
SPG
53
2
DIS
54
2
NTRS
44
5
CMG
53
-11
DVA
80
4
ADM
33
5
PSX
34
2
SIG
57
7
PPL
67
5
RSG
65
3
VFC
56
11
Financhill
Back

Intellia Therapeutics 10K Form

Sell
27

NTLA
Intellia Therapeutics

Last Price:
22.06
Seasonality Move:
1.88%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $36.28M
Cash Flow: $-59.2M
Price / Cash Flow: 0
Annual Sales: $9.88
Price / Book: 2.31

Profitability

EPS (TTM): -5.48000
Net Income (TTM): $-508.8M
Gross Margin: --
Return on Equity: -48.93%
Return on Assets: -40.26%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,199.36% of Revenue.
  • The Net Earning history of NTLA is -1,326.51% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 1 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.21
Quick Ratio: 6.69

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
27
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?